<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02237534</url>
  </required_header>
  <id_info>
    <org_study_id>CKDR-002</org_study_id>
    <nct_id>NCT02237534</nct_id>
  </id_info>
  <brief_title>Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia</brief_title>
  <acronym>LAVALIER</acronym>
  <official_title>Lanthanum Carbonate Versus Calcium Carbonate for Vascular Abnormalities in Patients With Chronic Kidney Disease and Hyperphosphatemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osaka University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Osaka University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of lanthanum carbonate and calcium
      carbonate on the progression of coronary calcification and vascular endothelial dysfunction.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>September 2014</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary artery calcification score</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by EndoPAT™ (Itamar Medical Ltd.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum bone metabolic markers</measure>
    <time_frame>3 months</time_frame>
    <description>Bone specific alkaline phosphatase (BAP) and Tartrate-resistant acid phosphatase 5b (TRACP5b)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum bone metabolic markers</measure>
    <time_frame>1 year</time_frame>
    <description>Bone specific alkaline phosphatase (BAP) and Tartrate-resistant acid phosphatase 5b (TRACP5b)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of calcium, phosphate, intact parathyroid hormone, 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D over time</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate over time</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum osteoprotegerin concentration</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum osteoprotegerin concentration</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary alpha-Klotho to creatinine ratio</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary alpha-Klotho to creatinine ratio</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary liver-type fatty acid binding protein (L-FABP) to creatinine ratio</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary liver-type fatty acid binding protein (L-FABP) to creatinine ratio</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-stage renal disease requiring renal replacement therapy</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular event requiring hospitalization</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Acute myocardial infarction, angina pectoris, congestive heart failure, stroke, and peripheral vascular disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Micro RNA array</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hypercalcemia</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Corrected serum calcium concentration ≥11.0 mg/dL</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypocalcemia</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Corrected serum calcium concentration &lt;8.5 mg/dL</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <condition>Hyperphosphatemia</condition>
  <condition>Bone Diseases, Metabolic</condition>
  <arm_group>
    <arm_group_label>Calcium carbonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Start at a dose of 1,500 mg/day, and adjust it to lower serum phosphate concentration &lt;4.5 mg/dL. Maximum dose is 3,000 mg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lanthanum carbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Start at a dose of 750 mg/day, and adjust it to lower serum phosphate concentration &lt;4.5 mg/dL. Maximum dose is 1,500 mg/day. For patients with calcium carbonate at inclusion, calcium carbonate will be replaced with lanthanum carbonate of 750 mg/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanthanum carbonate</intervention_name>
    <arm_group_label>Lanthanum carbonate</arm_group_label>
    <other_name>FOSRENOL®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Carbonate</intervention_name>
    <arm_group_label>Calcium carbonate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hyperphosphatemia (For patients without calcium carbonate, ≥4.5 mg/dL) (For patients
             with calcium carbonate, ≥4.0 mg/dL)

          -  With written informed consent

        Exclusion Criteria:

          -  History of cardiac surgery

          -  With coronary artery stent

          -  Polycystic kidney disease

          -  Hypothyroidism

          -  On treatment with lanthanum carbonate

          -  History of admission within 3 months

          -  History of ileus

          -  Severe liver dysfunction

          -  Severe gastrointestinal dysfunction

          -  Allergy to lanthanum carbonate or calcium carbonate

          -  Pregnant or breastfeeding women

          -  Judged as ineligible by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takayuki Hamano, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Comprehensive Kidney Disease Research, Osaka University Graduate School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2014</study_first_submitted>
  <study_first_submitted_qc>September 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2014</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Osaka University</investigator_affiliation>
    <investigator_full_name>Yoshiharu Tsubakihara</investigator_full_name>
    <investigator_title>Endowed chair</investigator_title>
  </responsible_party>
  <keyword>Lanthanum</keyword>
  <keyword>Calcium Carbonate</keyword>
  <keyword>Vascular Calcification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Hyperphosphatemia</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

